NCT02101593View on ClinicalTrials.gov

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

March 31, 2016

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

ADI-PEG 20

Trial Locations (2)

10065

Memorial Sloan-Kettering Cancer Center, New York

98109-1023

Seattle Cancer Care Alliance, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Polaris Group

INDUSTRY